Actionable news
0
All posts from Actionable news
Actionable news in TRIL: TRILLIUM THERAPEUTICS INC,

Trillium Therapeutics Announces Conference Call and Webcast on December 5th to Discuss TTI-621 Data Presented at ASH

TORONTO, ONTARIO--(Marketwired - Nov 29, 2016) - Trillium Therapeutics Inc. (TR.TO)(TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will host a conference call and webcast at 8:30 a.m. ET (5:30 a.m. PT) on Monday, Dec. 5, 2016, to discuss the poster presentation on its lead drug candidate, TTI-621, at the American Society of Hematology (ASH) 58th Annual Meeting in San Diego. Trillium will present initial clinical data from its ongoing TTI-621 hematologic malignancy Phase 1 trial at ASH.

The conference call may be accessed by dialing:

  • U.S. callers: (844) 358-6757
  • International callers: (216) 562-0400
  • Conference ID: 28772974.

The conference call will also be available via a live webcast on the investors section of Trillium's website at www.trilliumtherapeutics.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. Following the call, an archived...


More